The best treatment doctors currently have for stroke can accelerate the death of brain cells in addition to dissolving blood clots, researchers report in the journal Nature Medicine. But they also found good news: Another drug currently used to treat patients with severe sepsis counters the harmful effects, offering the possibility that a combination of two already-approved drugs might offer a powerful new stroke treatment that would give doctors a bigger window of time to treat patients.
The work is the result of a longstanding collaboration between scientists at the University of Rochester Medical Center and counterparts at Scripps Research Institute in La Jolla, Calif. The team found that the clot-buster tPA (tissue plasminogen activator) can magnify the harmful effects of stroke in mice and in human cells, and that a compound known as APC (activated protein C) counters the harmful effects. "TPA has been a great therapy for some patients, but right now its available to a tiny minority of patients. We hope to extend the window of opportunity that tPA could be given, by protecting the brain against its toxic effects," says Berislav Zlokovic, M.D., Ph.D., the Rochester neuroscientist who led the research thanks to funding from the National Heart, Lung and Blood Institute. "This holds great promise for stroke therapy."
TPA is best known as a clot buster useful for patients who have the most common type of stroke, where a blood clot blocks blood flow to a portion of the brain, cutting off oxygen. The trauma causes more and more brain cells to die as they try to cope with the damage. The result can be a devastating brain injury that incapacitates the person for life.
Tom Rickey | EurekAlert!
Fingerprint' technique spots frog populations at risk from pollution
27.03.2017 | Lancaster University
Parallel computation provides deeper insight into brain function
27.03.2017 | Okinawa Institute of Science and Technology (OIST) Graduate University
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
27.03.2017 | Earth Sciences
27.03.2017 | Life Sciences
27.03.2017 | Life Sciences